Novavax (NVAX) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Novavax (NVAX) is set to release its Q2 2025 earnings on August 6th, with projections of a loss of ($0.12) per share and revenue of $149.19 million.
• The company's recent earnings report revealed a substantial profit of $2.93 EPS, significantly surpassing analysts' expectations and showcasing a 610.3% increase in year-over-year revenue.
• Currently, Novavax has an average rating of "Hold" from analysts, with price targets ranging from $6.00 to $15.86, indicating cautious outlooks amid mixed ratings.

Novavax (NASDAQ:NVAX - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Novavax to post earnings of ($0.12) per share and revenue of $149.19 million for the quarter. Novavax has set its FY 2025 guidance at EPS.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.71 by $2.22. The firm had revenue of $666.66 million during the quarter, compared to analyst estimates of $204.08 million. Novavax had a negative return on equity of 115.51% and a net margin of 38.14%. The firm's quarterly revenue was up 610.3% on a year-over-year basis. During the same period last year, the company posted ($1.05) EPS. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Novavax Stock Down 2.9%

NASDAQ NVAX traded down $0.20 on Thursday, reaching $6.65. 4,870,119 shares of the stock traded hands, compared to its average volume of 6,431,046. The firm's fifty day simple moving average is $6.96 and its 200 day simple moving average is $7.27. The company has a market cap of $1.08 billion, a price-to-earnings ratio of 2.51, a P/E/G ratio of 0.09 and a beta of 2.69. Novavax has a 12 month low of $5.01 and a 12 month high of $15.22.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. cut their price objective on Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a research report on Friday, May 9th. Citigroup assumed coverage on Novavax in a research report on Tuesday, June 17th. They set a "sell" rating and a $6.00 price objective for the company. B. Riley reiterated a "buy" rating on shares of Novavax in a research report on Monday, May 19th. Finally, Bank of America reduced their target price on Novavax from $10.00 to $9.00 and set a "neutral" rating for the company in a report on Tuesday, July 22nd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Novavax presently has an average rating of "Hold" and a consensus price target of $15.86.

Institutional Trading of Novavax

Hedge funds and other institutional investors have recently modified their holdings of the company. Caxton Associates LLP purchased a new stake in shares of Novavax during the first quarter worth $158,000. Strs Ohio acquired a new position in Novavax during the first quarter worth $167,000. AQR Capital Management LLC increased its position in Novavax by 95.2% during the first quarter. AQR Capital Management LLC now owns 44,427 shares of the biopharmaceutical company's stock worth $285,000 after buying an additional 21,663 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Novavax by 2.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company's stock worth $678,000 after buying an additional 2,750 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Novavax by 16.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 312,789 shares of the biopharmaceutical company's stock worth $2,005,000 after buying an additional 44,105 shares during the last quarter. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.